CRSP (CRISPR Therapeutics AG) ROCE %: -22.14% (As of Mar. 2026)

What is CRISPR Therapeutics AG ROCE %?

CRISPR Therapeutics AG CRSP +4.63% 41 ROCE % is -22.14% as of Mar. 2026. GuruFocus rates CRSP with a GF Score™ of 41/100 and a GF Value™ of $2.42 (Significantly Overvalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. CRISPR Therapeutics AG's annualized ROCE % for the quarter that ended in Mar. 2026 was -22.14%.

CRISPR Therapeutics AG (NAS:CRSP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

CRISPR Therapeutics AG ROCE % Related Terms

CRISPR Therapeutics AG ROCE % Historical Data

* Premium members only.

The historical data trend for CRISPR Therapeutics AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CRISPR Therapeutics AG ROCE % Chart

CRISPR Therapeutics AG Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

17.11

-28.32

-10.49

-21.83

-31.12

CRISPR Therapeutics AG Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-28.27	-46.19	-26.07	-29.18	-22.14

41GF Score

CRISPR Therapeutics AG CRSP

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

CRISPR Therapeutics AG ROCE % Calculation

CRISPR Therapeutics AG's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-664.571	/	( ( (2242.034 - 87.782)	+	(2265.243 - 149.12) )	/ 2 )
	=	-664.571	/	( (2154.252	+	2116.123)	/ 2 )
	=	-664.571	/	2135.1875
	=	-31.12 %

CRISPR Therapeutics AG's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-520.992	/	( ( (2265.243 - 149.12)	+	(2725.82 - 136.286) )	/ 2 )
	=	-520.992	/	( ( 2116.123	+	2589.534 )	/ 2 )
	=	-520.992	/	2352.8285
	=	-22.14 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -22.14% mean?

CRISPR Therapeutics AG (CRSP) has a ROCE % of -22.14% as of Mar. 2026.

Is CRISPR Therapeutics AG's ROCE % too high?

CRISPR Therapeutics AG's current ROCE % is -22.14%. Overall, CRISPR Therapeutics AG has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does CRISPR Therapeutics AG's ROCE % compare to CGON and XENE?

CRISPR Therapeutics AG's ROCE % of -22.14% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Biotechnology company?

A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. CRISPR Therapeutics AG's current ROCE % is -22.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is CRISPR Therapeutics AG stock overvalued right now?

Based on GuruFocus' analysis, CRISPR Therapeutics AG (CRSP) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.42, compared to a current price of $56.03 — trading 2215.3% above its estimated fair value. The current ROCE % is -22.14%. CRISPR Therapeutics AG's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For CRISPR Therapeutics AG (CRSP), the current ROCE % is -22.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CRISPR Therapeutics AG (CRSP) Overvalued in 2026?

Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued. The current stock price of $56.03 is trading 2215.3% above its estimated GF Value™ of $2.42. GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.

Key valuation signals for CRSP:

ROCE %: -22.14%
GF Value™: $2.42 vs. price of $56.03 (2215.3% above fair value)
GF Score™: 41/100 with 4 warning signs

No single metric tells the full story. See the CRSP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CRISPR Therapeutics AG Business Description

Industry Healthcare Biotechnology

Comparable Companies CGON XENE DNTH LEGN TGTX SRRK COGT RYTM CAI PTCT VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges CRSPN:Mexico 0VRQ:UK 1CG:Germany C2RS34:Brazil

Address Baarerstrasse 14, Zug, CHE, 6300

Website https://www.crisprtx.com

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

41GF Score

Get the complete analysis for CRSP

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$56.03

Price

$2.42

GF Value

View CRSP Analysis

See ROCE % data for all stocks →